Physician profile
Mark A Moffet
NPI 1477690345
$1,246.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $295.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $270.68 | 2019-2020 | |
| Allergan, INC. | $190.50 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $190.44 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $167.45 | 2019-2020 | |
| Lundbeck LLC | $156.77 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $100.69 | 2019-2020 | |
| Alkermes, INC. | $68.26 | 2019 | |
| Indivior INC. | $33.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $24.70 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.55 | 2019 | |
| Shire North American Group INC | $15.27 | 2019 | |
| Validus Pharmaceuticals LLC | $12.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Moffet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.